Tag: Aequus Pharmaceuticals (AQS.V)
-
![Aequus Pharmaceuticals (AQS.V) Sees All, Partners with ReVision Therapeutics to Tackle Stargardt Disease]()
Aequus Pharmaceuticals (AQS.V) Sees All, Partners with ReVision Therapeutics to Tackle Stargardt Disease
I have a bit of a sweet tooth. When I was little, my dad used to buy me those massive 64-ounce Jelly Belly containers from Costco. Even that wasn’t enough to satiate my craving for sugar seeing as I would finish the entire thing in just a few days. Eventually, I grew out of my…
-
![Aequus Pharma (AQS.V) update including Q1,2021 financial highlights]()
Aequus Pharma (AQS.V) update including Q1,2021 financial highlights
On May 31, 2021 Aequus Pharmaceuticals (AQS.V) reported financial results for Q1, 2021. Aequus is a $19 million pharmaceutical company focused on developing and commercializing high quality, differentiated products. AQS is building a Canadian commercial platform through its own development pipeline and through license-acquisition. On November 20, 2020 Equity Guru’s Chris Parry spoke with Aequus’…
-
![Aequus Pharma (AQS.V) launches Evolve Eyedrops to eye care professionals in Canada]()
Aequus Pharma (AQS.V) launches Evolve Eyedrops to eye care professionals in Canada
Aequus is a $24 million pharmaceutical company focused on developing and commercializing high quality, differentiated products.
-
![Aequus (AQS.V) gains a new medical device licence for $90 million Canadian Dry Eye Disease market]()
Aequus (AQS.V) gains a new medical device licence for $90 million Canadian Dry Eye Disease market
Currently in Canada, the dry eye market is estimated at over $9O million, which includes both prescription and over-the-counter products.
